logo

Glenmark Launches Generic INLYTA Cancer Tablets in US; Shares Rise 1.4%

Authored By HDFC SKY | Published at: Nov 16, 2026 10:15 AM IST

Glenmark Pharmaceuticals Limited shares rose around 1.4% on Monday, November 16, 2026, after its US subsidiary launched an authorised generic version of INLYTA (axitinib) tablets in 1 mg and 5 mg strengths. The original drug recorded approximately $538.4 million in annual US sales for the 12 months ended September 2026. The launch follows Glenmark’s Q2 FY27 results, which showed adjusted profit after tax of ₹485.2 crore and consolidated revenue of ₹4,247.3 crore.

Stocks in News
GLENMARK
₹2,655
0.57%
Glenmark Launches Generic INLYTA Cancer Tablets in US; Shares Rise 1.4%

Open Free Demat Account

By signing up I certify terms, conditions & privacy policy

Mumbai, November 16: Glenmark Pharmaceuticals Limited shares moved higher on Monday after the company announced the launch of an authorised generic version of INLYTA (axitinib) tablets in the United States. The product, available in 1 mg and 5 mg strengths, has been introduced by its US subsidiary, Glenmark Pharmaceuticals Inc. The announcement marks another addition to the company’s North American pharmaceutical portfolio. Glenmark shares climbed towards ₹2,680 during early trading, compared with the previous closing price of ₹2,640.

Glenmark Launches Generic INLYTA Tablets in the US

Glenmark Pharmaceuticals Inc., USA, announced the launch of axitinib tablets in 1 mg and 5 mg strengths on November 16, 2026. The product is an authorised generic version of INLYTA, a medicine marketed by Pfizer and used in the treatment of certain patients with advanced renal cell carcinoma, a form of kidney cancer. According to IQVIA sales data cited by Glenmark, INLYTA tablets recorded approximately $538.4 million in annual US sales during the 12 months ended September 2026. The figure represents the overall US sales of the reference product and should not be interpreted as Glenmark’s expected revenue from the launch. The company said the introduction of axitinib tablets supports its efforts to expand access to affordable medicines in the United States. Mark Kickul, President and Business Head, North America, said the addition reinforces Glenmark’s commitment to improving medicine accessibility while expanding its product portfolio. The launch strengthens Glenmark’s presence in the US generics market, particularly in oncology, although the company has not disclosed expected sales or earnings contributions from the product.

Glenmark Q2 FY27 Adjusted Profit Stands at ₹485.2 Crore

Glenmark had announced its financial results for the quarter ended September 30, 2026, on November 5. The company reported consolidated revenue from operations of ₹4,247.3 crore, compared with ₹6,046.9 crore in the corresponding quarter last year. While reported revenue declined approximately 29.8% year-on-year, the company said revenue increased around 20% on a like-for-like basis, reflecting the impact of differences in revenue recognition between the two periods. EBITDA stood at ₹863.8 crore, with an EBITDA margin of 20.3%. Adjusted profit after tax reached ₹485.2 crore, representing an adjusted PAT margin of 11.4%. Reported profit after tax stood at ₹263.8 crore. The company reported revenue of ₹1,208.9 crore from North America during the September quarter. Excluding deferred out-licensing income recognition related to ISB 2001, the region’s core business grew approximately 31% year-on-year. India formulations recorded revenue of ₹1,327.4 crore, with like-for-like growth of approximately 14%. Emerging Markets revenue increased 33.2%, while Europe recorded 6.2% growth. The results highlighted improving performance across Glenmark’s underlying pharmaceutical business, although reported consolidated revenue remained below the year-earlier level.

US Product Launch Supports Glenmark’s North America Strategy

Glenmark has been expanding its US portfolio through generic medicines, differentiated products and new launches across therapeutic categories. During Q2 FY27, the company introduced several products in North America, including Sugammadex Injection, Fluticasone Nasal Spray and Nintedanib Capsules. As of September 30, 2026, Glenmark had 229 generic products authorised for distribution in the US market, with 51 applications pending at various stages of the US Food and Drug Administration approval process. The latest axitinib launch adds another oncology product to its portfolio. While the reference product has an established US market, Glenmark’s commercial performance will depend on competition, pricing, distribution and the share of demand captured by its authorised generic.

Stock Market Snapshot

Glenmark Pharmaceuticals share price were trading around ₹2,676 during the morning session on Monday, November 16, 2026, up approximately ₹36 or 1.36% from the previous NSE closing price of ₹2,640. According to the supplied intraday chart, the stock initially traded near ₹2,649 before declining towards ₹2,642 during early trading. Buying interest subsequently improved, pushing the share price above ₹2,650 around 9:15 AM IST. The stock continued to gain momentum and moved above ₹2,670 before 9:30 AM IST. It briefly approached ₹2,680 around 9:40 AM IST before easing slightly. By approximately 9:43 AM IST, shares remained near ₹2,676, reflecting positive early trading momentum. The rise coincided with the company’s announcement of its authorised generic axitinib launch in the US.

Glenmark Pharmaceuticals Limited

About Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Limited is a Mumbai-based global pharmaceutical company engaged in the research, development, manufacturing and marketing of medicines. The company operates across branded formulations, generic medicines, innovative therapies and consumer healthcare products, with a focus on respiratory, dermatology and oncology treatments. Glenmark has manufacturing and research facilities across multiple countries and a commercial presence in more than 80 markets.

Conclusion

Glenmark Pharmaceuticals’ launch of authorised generic axitinib tablets in the United States marks another addition to its North American oncology portfolio. The reference product’s $538.4 million annual US sales indicate the size of the existing market, although Glenmark’s potential revenue contribution remains undisclosed. The announcement comes after the company’s Q2 FY27 results showed growth in its underlying business and an adjusted profit of ₹485.2 crore. Shares traded higher during Monday’s morning session, with future performance dependent on product commercialisation, pricing competition and sustained growth across key markets.

Source: 

  • https://www.nseindia.in/get-quote/equity/GLENMARK/Glenmark-Pharmaceuticals-Limited
Disclaimer

The information shared here is intended solely for informational and educational purposes and does not constitute investment recommendations. While we practice strict due diligence in curating daily market data, readers must perform independent research before trading. To flag any real-time data discrepancies or content concerns, please write to us at content@hdfcsec.com.

Summarize with AI
Google GeminiChatGPTPerplexity AIAnthropic AIGrok AI
Desktop BannerMobile Banner

Invest Anytime, Anywhere

Get it on Google PlayGet it on App Store

Open Free Demat Account Online

By signing up I certify terms, conditions & privacy policy